
    
      Purpose of Phase I:

      the main purpose: To evaluate the safety of PLD in combination with cyclophosphamide,
      vincristine, regenerative, and refractory solid tumors in children, including dose absorption
      toxicity (DLT)

      Secondary purpose:

        -  determine the appropriate maximum tolerated dose (MTD) and /or PLD for further clinical
           studies in this patient population;

        -  Describe the antitumor activity of PLD combined with cyclophosphamide and vincristine in
           children with advanced solid tumors or primary CNS tumors;

      Exploratory purpose:

      Effectiveness of PLD combined with cyclophosphamide and vincristine in treatment progress,
      relapse, and refractory solid tumors in children.
    
  